OvaScience is a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility. Specifically, we are developing cell therapies for infertility and are seeking outstanding research associates to join our team. We are developing these treatments through the generation of developmentally competent human oocytes in vitro from a woman’s own Egg Precursor (EggPCSM) cell. These oocytes will have the potential to develop into normal embryos and thus address the unmet medical need for the generation of new eggs for patients who are unable to undergo conventional in vitro fertilization (IVF) treatments and have their own biological child.
OvaScience is looking for a Research Associate(s) to join our Research team. This position, based in Waltham, MA, will focus on cell culture, as well as related cell biology experiments (to determine optimal culture conditions for differentiation and maturation of the stem-cell-derived oocytes). Under the supervision of a Director of Research, the Research Associate(s) will be responsible for following standard operating protocols in thawing cells, culture and maintenance of primary cells and oocytes, making necessary culture media and buffers, assays to characterization the quality of differentiated cells and to determine functionality of the oocytes.
Candidates must be authorized to work in the United States. OvaScience offers competitive salaries and benefits including medical, dental, and vision coverage, a 401(k) plan with company match, stock options, education assistance, time off, and other wellness initiatives.
OvaScienceSM, Inc. (NASDAQ:OVAS) is a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing OvaPrimeSM, which could increase a woman’s egg reserve and OvaTureSM, a potential in vitro fertilization (IVF) treatment that could help a woman produce new, fertilizable eggs without hormone injections. OvaScience’s AUGMENTSM treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in Canada and Japan. OvaScience treatments are not available in the U.S. For more information, visit www.ovascience.com.